{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:59:12Z","timestamp":1790765952697,"version":"4.1.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Development of chronic kidney disease (CKD) in type 2 diabetes mellitus (T2DM) is a dual threat, imposing not only increased risk for end-stage renal disease but also substantially increasing cardiovascular risk and premature mortality. Its prevalence is staggering, affecting approximately 30%\u201340% of all patients with T2DM. Fortunately, advances in pharmacotherapies over the past 25 years, including sodium\u2013glucose cotransporter 2 inhibitors, non-steroidal mineralocorticoid receptor antagonists and glucagon-like peptide-1 receptor agonists, together with blockade of renin\u2013angiotensin aldosterone system activation with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, have transformed the clinical management of T2DM and CKD. By providing parallel reductions in both renal and cardiovascular risk, patients with T2DM and CKD (especially those at higher risk) experience improved survival, fewer cardiovascular events and require less initiation of dialysis as a result of delayed progression to end-stage renal failure. Recent evidence from clinical trials in T2DM and CKD supports simultaneous use of combinatory pharmacotherapies targeting distinct mechanistic pathophysiological pathways.<\/jats:p>","DOI":"10.1093\/ndt\/gfag136","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:50:10Z","timestamp":1781178610000},"page":"1927-1929","source":"Crossref","is-referenced-by-count":0,"title":["Combination pharmacotherapy in type 2 diabetes and chronic kidney disease: translating evidence into clinical practice"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8234-9155","authenticated-orcid":false,"given":"Julie A","family":"Lovshin","sequence":"first","affiliation":[{"name":"Sunnybrook Health Science Centre , Department of Medicine, Toronto, ON M4N 3M5 ,","place":["Canada"]},{"name":"Banting and Best Diabetes Centre , Toronto, ON M5G 2C4 ,","place":["Canada"]},{"name":"Temetry Faculty of Medicine, Divison of Endocrinology and Metabolism, University of Toronto , Toronto, ON M5S 1A8 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"2026093006071398500_bib1","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026093006071398500_bib2","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic kidney disease diagnosis and management: a review","volume":"322","author":"Chen","year":"2019","journal-title":"JAMA"},{"key":"2026093006071398500_bib3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.kint.2020.06.024","article-title":"Executive summary of the 2020 KDIGO diabetes management in CKD guideline: evidence based advances in monitoring and treatment","volume":"98","author":"de\u00a0Boer","year":"2020","journal-title":"Kidney Int"},{"key":"2026093006071398500_bib4","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"The global burden of chronic kidney disease","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"2026093006071398500_bib5","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1152\/physrev.00045.2011","article-title":"Mechanisms of diabetic complications","volume":"93","author":"Forbes","year":"2013","journal-title":"Physiol Rev"},{"key":"2026093006071398500_bib6","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","article-title":"Renal hemodynamic effect of sodium glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus","volume":"129","author":"Cherney","year":"2014","journal-title":"Circulation"},{"key":"2026093006071398500_bib7","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2026093006071398500_bib8","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"2026093006071398500_bib9","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026093006071398500_bib10","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2026093006071398500_bib11","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026093006071398500_bib12","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026093006071398500_bib13","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026093006071398500_bib14","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2026093006071398500_bib15","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.jacc.2025.08.027","article-title":"Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 patients","volume":"86","author":"Galili","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026093006071398500_bib16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on Chronic Kidney Disease in Patients wtih Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026093006071398500_bib17","first-page":"100671","article-title":"A Systematic Literature Review of Coordinated Care in Cardiovascular-Kidney Metabolic Condition","volume":"9","author":"Duru","year":"2025","journal-title":"Mayo Clin Proc: Innov Qual Outcomes"},{"key":"2026093006071398500_bib18","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1056\/NEJMoa2410659","article-title":"Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes","volume":"993","author":"Agarwal","year":"2025","journal-title":"N Engl J Med"},{"key":"2026093006071398500_bib19","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMe2508784","article-title":"Combination Therapy for Chronic Kidney Disease and Type 2 Diabetes","volume":"393","author":"Zoccali","year":"2025","journal-title":"N Engl J Med"},{"key":"2026093006071398500_bib20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/20543581221127940","article-title":"Briding Gaps in Diabetic Nephropathy Care: A Narrative Review Guided by the Lived Experiences of Patient Partners","volume":"9","author":"Beaubien-Souligny","year":"2022","journal-title":"Can J Kidney Health Dis"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag136\/70685001\/gfag136.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/10\/1927\/70685001\/gfag136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/10\/1927\/70685001\/gfag136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:07:20Z","timestamp":1790762840000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/10\/1927\/8763805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":20,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,8,18]]},"published-print":{"date-parts":[[2026,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfag136","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,8,18]]}}}